Table 5.
OS | PFS | |||||||
---|---|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | |||||
HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
Age | 1.015 (0.969–1.063) | 0.526 | 0.968 (0.902–1.038) | 0.359 | 1.009 (0.965–1.056) | 0.686 | 0.968 (0.910–1.031) | 0.313 |
Histologic type | 0.287 | 0.140 | 0.729 | 0.202 | ||||
Classic | ||||||||
D/N | 0.541 (0.132–2.218) | 0.392 | 0.138 (0.011–1.774) | 0.164 | 0.746 (0.279–1.991) | 1.000 | 0.280 (0041–1.910) | 0.274 |
LC/A | 1.632 (0.554–4.805) | 0.310 | 1.688 (0.276–10.328) | 1.000 | 1.205 (0.483–3.005) | 1.000 | 1.548 (0.301–7.960) | 1.000 |
CTNNB1 | ||||||||
Mutant (vs. wild) | 0.247 (0.037–2.028) | 0.205 | 0.627 (0.065–6.019) | 0.627 | 0.410 (0.097–1.721) | 0.223 | 0.892 (0.169–4.721) | 0.893 |
Ror2 mRNA | ||||||||
High expression (vs. low) | 0.388 (0.152–0.995) | 0.049 | 0.179 (0.036–0.879) | 0.034 | 0.360 (0.152–0.851) | 0.020 | 0.213 (0.054–0.845) | 0.213 |
Wnt5a mRNA | ||||||||
High expression (vs. low) | 0.759 (0.309–1.863) | 0.547 | 2.755 (0.524–14.488) | 0.232 | 0.748 (0.337–1.661) | 0.476 | 1.556 (0.410–5.902) | 0.516 |
MYCC | ||||||||
Amplification (vs. no amplification) | 1.039 (0.386–2.800) | 0.939 | 0.838 (0.131–5.362) | 0.852 | 1.039 (0.386–2.800) | 0.939 | 0.973 (0.231–4.099) | 0.970 |
MYCN | ||||||||
Amplification (vs. no amplification) | 1.558 (0.662–3.664) | 0.310 | 2.550 (0.873–7.447) | 0.087 | 1.824 (0.864–3.849) | 0.761 | 4.157 (0.906–10.757) | 0.083 |
Metastasis | ||||||||
Metastasis (vs. no metastasis) | 2.756 (1.143–6.642) | 0.024 | 3.489 (0.968–12.574) | 0.056 | 0.870 (0.355–2.131) | 0.296 | 1.700 (0.508–5.685) | 0.389 |
Primary surgery type | ||||||||
Non‐GTR (vs. GTR) | 2.522 (1.142–5.570) | 0.022 | 0.966 (0.526–3.652) | 0.966 | 2.887 (1.410–5.912) | 0.004 | 1.469 (0.500–4.317) | 0.484 |
Postoperative treatment | ||||||||
Yes (vs. No) | 0.062 (0.019–0.205) | <0.001 | 0.047 (0.008–0.269) | 0.001 | 0.105 (0.034–0.325) | <0.001 | 0.147 (0.032–0.678) | 0.014 |